ArticleeLife2018
Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins.
Open access · goldAbstract read
In one paragraph
Article in eLife, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
8.4field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 98 citations in OpenAlex.
- ELOVL6 activity attenuation induces mutant KRAS degradation.Nature chemical biology · 2026Article
- Pan-cancer N-glycoproteomic atlas of patient-derived xenografts uncovers FAT2 as an actionable surface target.Cell reports. Medicine · 2026Article
- Lung adenocarcinoma surfaceome remodeling with EGFR inhibitors uncovers placental alkaline phosphatase as a target for combination therapy.Cell reports. Medicine · 2025Article
- Hijacking Extracellular Targeted Protein Degrader-Drug Conjugates for Enhanced Drug Delivery.Journal of the American Chemical Society · 2025Article
- CDCP1-targeting ADC outperforms standard therapies in Ras-mutant pancreatic cancer.Molecular therapy. Oncology · 2025Article
- Low-density lipoprotein receptor-targeting chimeras for membrane protein degradation and enhanced drug delivery.bioRxiv : the preprint server for biology · 2025Article
- Engineered Proteins and Chemical Tools to Probe the Cell Surface Proteome.Chemical reviews · 2025Review
- Recent Advances in Small Molecular PET Tracers for Pancreatic Cancer Diagnosis: Preclinical Stage.Mini reviews in medicinal chemistry · 2025Review
- N-Terminomic Identification of Intracellular MMP-2 Substrates in Cardiac Tissue.Journal of proteome research · 2024Article
- A general approach for selection of epitope-directed binders to proteins.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Secreted HLA-Fc fusion profiles immunopeptidome in hypoxic PDAC and cellular senescence.PNAS nexus · 2023Article
- Recent advances in targeting the "undruggable" proteins: from drug discovery to clinical trials.Signal transduction and targeted therapy · 2023Review
- Efficient Generation of Paired Single-Cell Multiomics Profiles by Deep Learning.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Theranostic Targeting of CUB Domain-Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Mechanistic insights into CDCP1 clustering on non-small-cell lung cancer membranes revealed by super-resolution fluorescent imaging.iScience · 2023Article
- Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins.Nature biotechnology · 2023Article
- Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors.eLife · 2022Article
- Direct Identification of Proteolytic Cleavages on Living Cells Using a Glycan-Tethered Peptide Ligase.ACS central science · 2022Article
- Glycoproteomics Identifies Plexin-B3 as a Targetable Cell Surface Protein Required for the Growth and Invasion of Triple-Negative Breast Cancer Cells.Journal of proteome research · 2022Article
- The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance.Nature communications · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Alexander J MartinkoDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States.ORCID http://orcid.org/0000-0002-4025-959X
Charles TruilletDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, United States.
Olivier JulienDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States.ORCID http://orcid.org/0000-0001-7068-7299
Juan E DiazDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States.
Max A HorlbeckDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States.ORCID http://orcid.org/0000-0002-3875-871X
Gordon WhiteleyCancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, United States.
Josip BlonderCancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, United States.
Jonathan S WeissmanDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States.ORCID http://orcid.org/0000-0003-2445-670X
Sourav BandyopadhyayDiller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, United States.ORCID http://orcid.org/0000-0003-3120-923X
Michael J EvansDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, United States.
James A WellsDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States.ORCID https://orcid.org/0000-0001-8267-5519
University of California, San Francisco · USFrederick National Laboratory for Cancer Research · USHoward Hughes Medical Institute · US
Funding
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007618 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANDERSON, MARK S · 1985 to 2020
$29.6MRESEARCH TRAINING IN CHEMISTRY AND CHEMICAL BIOLOGYT32GM064337 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CRAIK, CHARLES SCOTT · 2002 to 2021
$7.8MSurfaceomic technologies and antibodies to probe cell surface proteomes and their interactomes at unprecedented small scale and high-resolutionR35GM122451 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JAMES A WELLS · 2017 to 2026
$5.3MThe Cancer Target Discovery and Development Network at UCSFU01CA217882 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BANDYOPADHYAY, SOURAV, BIVONA, TREVER G · 2017 to 2021
$5.2MIntegrative Program in Complex Biological System (ipCBS)T32EB009383 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARSHALL, WALLACE, WEINER, ORION D · 2009 to 2022
$3.2MAffinity-directed tagging of protein binding partners in signalingR01CA191018 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WELLS, JAMES A · 2014 to 2018
$1.6MRegulating Proteolysis to Dissect ApoptosisR01GM097316 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WELLS, JAMES A · 2011 to 2014
$1.1MNCI NIH HHS CA191018NCI NIH HHS R01 CA191018NCI NIH HHS U01 CA217882NIBIB NIH HHS T32 EB009383NIGMS NIH HHS GM097316NIGMS NIH HHS R01 GM097316NIGMS NIH HHS R35 GM122451NIGMS NIH HHS T32 GM007618NIGMS NIH HHS T32 GM064337
Abstract
While there have been tremendous efforts to target oncogenic RAS signaling from inside the cell, little effort has focused on the cell-surface. Here, we used quantitative surface proteomics to reveal a signature of proteins that are upregulated on cells transformed with KRAS
Indexed as
AntibodiesAntineoplastic AgentsCell Line, TumorDrug CarriersHumansImmunologic FactorsMembrane ProteinsMolecular Targeted TherapyNeoplasmsras ProteinsAntibodiesAntineoplastic AgentsDrug CarriersImmunologic FactorsMembrane Proteinsras Proteinsantibody engineeringbiochemistrycancer biologycancer target discoveryhumanmouseoncogenic RAS
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.